We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+46.36%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$8.12B
AUM Growth
+$2.18B
Cap. Flow
+$164M
Cap. Flow %
2.02%
Top 10 Hldgs %
63.91%
Holding
78
New
15
Increased
7
Reduced
2
Closed
11

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$98.6M
2
BLTE
Belite Bio
BLTE
+$57.4M
3
RNAM
Avidity Biosciences
RNAM
+$55.6M
4
LBRX
LB Pharmaceuticals
LBRX
+$28.2M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$25.4M

Top Sells

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$92.5M
2
RXST icon
RxSight
RXST
+$48.1M
3
TRML
Tourmaline Bio
TRML
+$40.6M
4
ELVN icon
Enliven Therapeutics
ELVN
+$17M
5
HNGE
Hinge Health
HNGE
+$15.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
2 Financials 0.1%
3 Miscellaneous 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GERN icon
26
Geron
GERN
$842M
$82.7M 1.02%
60,379,366
– –
TSHA icon
27
Taysha Gene Therapies
TSHA
$1.65B
$77M 0.95%
23,555,648
– –
BLTE
28
Belite Bio
BLTE
$6.82B
$64.8M 0.8%
+875,000
New +$57.4M
CLYM
29
Climb Bio
CLYM
$799M
$63.2M 0.78%
31,419,267
– –
SRRK icon
30
Scholar Rock
SRRK
$6.09B
$43.5M 0.54%
1,166,788
+30,335
+3% +$1.06M
GPCR icon
31
Structure Therapeutics
GPCR
$2.78B
$42.5M 0.52%
1,517,418
– –
MNPR icon
32
Monopar Therapeutics
MNPR
$700M
$41.8M 0.51%
511,207
– –
FDMT icon
33
4D Molecular Therapeutics
FDMT
$753M
$39.7M 0.49%
4,563,211
– –
SLDB icon
34
Solid Biosciences
SLDB
$897M
$35.9M 0.44%
5,811,423
+100
+0% +$585
MTSR
35
DELISTED
Metsera Inc
MTSR
$35.4M 0.44%
675,525
– –
ARTV
36
Artiva Biotherapeutics
ARTV
$436M
$28.3M 0.35%
9,853,302
– –
LBRX
37
LB Pharmaceuticals
LBRX
$1.39B
$28.1M 0.35%
+1,776,958
New +$28.2M
TVTX icon
38
Travere Therapeutics
TVTX
$5.89B
$27.5M 0.34%
1,150,000
– –
ASMB icon
39
Assembly Biosciences
ASMB
$532M
$26.1M 0.32%
+1,020,410
New +$22.4M
ABOS icon
40
Acumen Pharmaceuticals
ABOS
$209M
$25.5M 0.31%
14,932,063
– –
CTNM
41
Contineum Therapeutics
CTNM
$520M
$24.9M 0.31%
+2,122,000
New +$17.1M
NKTX icon
42
Nkarta
NKTX
$206M
$22.4M 0.28%
10,805,129
– –
LRMR icon
43
Larimar Therapeutics
LRMR
$406M
$19.5M 0.24%
6,045,351
– –
IVVD icon
44
Invivyd
IVVD
$245M
$18.8M 0.23%
+17,119,096
New +$15.2M
TNGX icon
45
Tango Therapeutics
TNGX
$4.03B
$16.8M 0.21%
2,000,000
– –
PRME icon
46
Prime Medicine
PRME
$570M
$16.6M 0.2%
+3,000,000
New +$12.2M
RCUS icon
47
Arcus Biosciences
RCUS
$3.1B
$15.5M 0.19%
1,136,364
– –
ACRV icon
48
Acrivon Therapeutics
ACRV
$78.4M
$15.1M 0.19%
8,340,508
– –
HOWL icon
49
Werewolf Therapeutics
HOWL
$47.6M
$13.2M 0.16%
6,681,307
– –
QURE icon
50
uniQure
QURE
$2.99B
$11.7M 0.14%
+200,000
New +$3.63M
1
2
3 4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, RA Capital Management held 78 positions worth $8.12B, up 37% from $5.94B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

RA Capital Management's Q3 2025 filing shows 15 new, 7 increased, 2 reduced and 11 closed positions. Its largest new stake was Nuvalent: 1,246,456 shares worth $108M. The largest sale was Dyne Therapeutics, an estimated $92.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials and Miscellaneous.

  • RA Capital Management's largest Q3 2025 buy was Nuvalent: 1,246,456 shares worth $108M.
  • RA Capital Management added most to Avidity Biosciences in Q3 2025, an estimated $55.6M increase.
  • RA Capital Management's biggest Q3 2025 reduction was Avalo Therapeutics, cutting an estimated $2.32M.
  • RA Capital Management fully exited Dyne Therapeutics in Q3 2025, selling an estimated $92.5M.
  • RA Capital Management's ten largest holdings make up 64% of its $8.12B portfolio in Q3 2025.
  • RA Capital Management opened 15 new positions and closed 11 in Q3 2025.
  • RA Capital Management's portfolio value rose 37% quarter-over-quarter to $8.12B.

Based on RA Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.